+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

  • PDF Icon

    Report

  • 120 Pages
  • January 2023
  • Region: Global
  • Renub Research
  • ID: 5715834

Age-Related Macular Degeneration Industry was US$ 8.62 Billion in 2022

Age-Related Macular Degeneration Market will reach US$ 14.06 Billion in 2028 according to the publisher. Age-related macular degeneration (AMD) is an eye ailment that may worsen over time. It is the prime cause of severe, permanent vision loss in people over 60. It occurs when the small central portion of the retina, called the macula, wears down. The aging of the population and the high incidence of the disease augment the market growth.

For instance, UNDESA published data of the population aged 65 years and above was around 727 Million in 2020. By the end of 2050, the geriatric population will be approximately 2 Billion. Dry macular and wet macular degeneration are the two main types of macula wear and tear leading to the disorder. Both are potentially lethal and require treatment with medication. The potential market for the treatment of age-related macular degeneration is growing in response to rising demand from the elderly. As per our research findings Age-related Macular Degeneration Industry will expand at a CAGR of 8.5% from 2022 to 2028.

The magnified reimbursement incentives for age-related macular degeneration (AMD) drugs contribute to the improvement of the industry. Furthermore, an increase in the occurrence of eye-related disorders and growth in the global elderly population drives the age-related macular degeneration market. In addition, the rising market trends, such as the advancement of gene therapy for age-related macular degeneration, will lead to the development of medical treatment for age-related macular degeneration. As per our research report, the Age-related Macular Degeneration Industry was US$ 8.62 Billion in 2022.

However, at present, only a few drugs, mainly anti-VEGFs, are approved for treating age-related macular degeneration. In addition, anti-VEGF drugs require repetitive and inconvenient intraocular injections, which increases the burden and results in non-adherence to treatment. Neither insurance nor Medicare will cover the value of such medications, slowing down the market expansion for AMD treatments. Market expansion may be bounded even by the strict FDA requirements.

Industry Trends:

Around the world, advanced AMD is a primary cause of permanent blindness and visual impairment. As a result, the market is growing as AMD's load grows. Further, according to the Canadian Ophthalmological Society, Wet age-related macular degeneration is one of the significant reasons for visual loss in adults over 65.
The anticipated launch of potential therapy may add to the market size in the future, assisted by a rise in the diagnosed frequent community of Age-related Macular Degeneration.

Upcoming treatment like OPT-302, KSI-301, RGX-314, AKST4290, and others has the prospects to create a significant positive shift in the Wet-AMD market size.

Companies are adopting various strategic alliances to expand in multiple regions. Investments in research have increased to develop treatment drugs for AMD.

Launch of New Products shall add to the Growth of Dry AMD

Based on type, the Age-related Macular Degeneration (AMD) Market is segmented into; Wet AMD and Dry AMD. Dry AMD shall witness the fastest growth over the forecast period due to the expected launch of promising product candidates and the disease load of dry AMD. Dry AMD results for 85-90% of all macular degeneration cases. The management of dry macular degeneration is presently limited to vitamin formulations. However, various novel therapeutic options for its treatment are now in the medical pipeline, such as Luminate, Zimura, and Intravitreal pegcetacoplan. The approval of these prospective candidates may augment the rise of the dry AMD segment in the future.

Eylea Products held the Highest Market Share

The Age-related Macular Degeneration (AMD) Market by product is categorized into Eylea, Lucentis, Beovu, and Others. The Eylea category dominated due to its widespread market penetration and patent protection. In 2011, intravitreal injection of aflibercept was authorized for Eylea by the FDA. It stops VEGF from working in wet AMD. Therefore, it treats diabetic macular edema, wet AMD, and macular edema. However, the demand for Beovu, on the other hand, is projected to grow at the significant rate during the projection period owing to its higher drying effectiveness, patent protection, and triumph in treating severe cases of wet AMD.

Reimbursement coverage will Augment the Growth of Specialty Pharmacies

By Distribution Chanel, the Age-related Macular Degenerative (AMD) Market is divided into Hospital Pharmacies, Specialty pharmacies, and online pharmacies. The specialty pharmacy segment will witness the fastest growth over the projection period due to the ease of drug accessibility and reimbursement coverage offered by specialty pharmacies. For instance, CVS Caremark provides Eylea, Lucentis, Avastin, and Beovu prescription insurance to eligible retirees and employees enrolled in the Public Employees Insurance Program (PEIP) program. This initiative will fuel segment growth.

However, the hospital pharmacy category accounted for a significant market share. The rise is due to the surge in the incidence of AMD. Also, the increased number of hospital patients for its treatment. For instance, as per the Royal National Institute of Blind People (RNIB), around 26.5 million people in 2021 were at high risk of developing this condition. Moreover, most patients managed with drugs, such as Eylea, Lucentis, and Beovu, are administered intravenously in hospitals under the supervision of competent specialists. Thus, the rising demand for AMD treatment will raise the number of hospital visits, propelling the market for this category.

North American Market will hold the Highest Market Share

North America has the highest market share and shall sustain its supremacy in the coming years. Some key factors driving the regional market include the increasing burden of the geriatric population, the rising prevalence of this disease, the presence of significant market players, and the increasing research and development activities in the region.

Furthermore, beneficial government initiatives, increased research partnerships, recent product launches, and a rise in AMD cases will boost the regional market's peak. For instance, according to the American Academy of Ophthalmology, around 15 million North Americans live with AMD.

Additionally, the European market will also hold one of the largest share throughout the forecast period, overgrowing. This rise can be due to the rising purchasing power to buy patented drugs and significant unmet needs in Europe. Moreover, lifestyle enhancements and new medications for macular degeneration will drive the region's demand for macular degeneration drugs.

Key Players:

Major players in the Age-related Macular Degeneration Market are F. Hoffman - La Roche Ltd., Bayer AG, Abbvie, GSK Plc., Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies, and Alimera Sciences Inc.

In February 2020 - Novartis AG received European Commission approval for the marketing of Beovu. It is an anti-VEGF agent utilized for treating wet-AMD patients.

In October 2021 - Roche's Susvimo received FDA approval and is anticipated to enter the U.S. in 2022. It is a refillable implant, particularly for LUCENTIS administration, with a refillable timing of six months.

In January 2022 - F. Hoffmann-La Roche Ltd'.s drug contender, Vabysmo (faricimab), with an injection administration interval of 4 weeks during loading dose, received U.S. FDA approval for the therapy of age-related macular degeneration.

The report titled 'Age-related Macular Degeneration (AMD) Market Global Forecast by Type (Wet AMD, and Dry AMD), Product (Eylea, Lucentis, Beovu, and Others), Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa), Company Analysis (F. Hoffman - La Roche Ltd., Bayer AG, Abbvie, GSK Plc., Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies, and Alimera Sciences Inc)' provides a detailed analysis of Age-related Macular Degeneration Market.

Type - Market breakup from 2 Viewpoints:

1. Wet AMD
2. Dry AMD

Product - Market breakup from 4 Viewpoints:

1. Eylea
2. Lucentis
3. Beovu
4. Others

Distribution Chanel - Market breakup from 3 viewpoints:

1. Hospital Pharmacy
2. Specialty Pharmacy
3. Online Pharmacy

Region - The market breakup of 5 Regions

1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East and Africa

The company has been covered from 3 Viewpoints:

  • Overview
  • Recent Development
  • Revenue

Company Analysis:

1. F. Hoffman - La Roche Ltd.
2. Bayer AG
3. Abbvie
4. GSK Plc.,
5. Novartis AG,
6. Regeneron Pharmaceuticals
7. Bausch Health Companies
8. Alimera Sciences Inc
Frequently Asked Questions about the Age-Related Macular Degeneration (AMD) Market

What is the estimated value of the Age-Related Macular Degeneration (AMD) Market?

The Age-Related Macular Degeneration (AMD) Market was estimated to be valued at $8.62 Billion in 2022.

What is the growth rate of the Age-Related Macular Degeneration (AMD) Market?

The growth rate of the Age-Related Macular Degeneration (AMD) Market is 8.5%, with an estimated value of $14.06 Billion by 2028.

What is the forecasted size of the Age-Related Macular Degeneration (AMD) Market?

The Age-Related Macular Degeneration (AMD) Market is estimated to be worth $14.06 Billion by 2028.

Who are the key companies in the Age-Related Macular Degeneration (AMD) Market?

Key companies in the Age-Related Macular Degeneration (AMD) Market include F, Hoffman, La Roche Ltd., Bayer AG, Abbvie, GSK Plc.,, Novartis AG,, Regeneron Pharmaceuticals and Alimera Sciences Inc.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Global Age Related Macular Degeneration Market

6. Market Share - Global Age Related Macular Degeneration Market
6.1 By Type
6.2 By Product
6.3 By Distribution Channel
6.4 By Region

7. Type - Global Age Related Macular Degeneration Market
7.1 Dry Age Related Macular Degeneration Market
7.2 Wet Age Related Macular Degeneration Market

8. Product - Global Age Related Macular Degeneration Market
8.1 Eylea
8.2 Lucentis
8.3 Beovu
8.4 Others

9. Distribution Channel - Global Age Related Macular Degeneration Market
9.1 Hospital Pharmacy
9.2 Specialty Pharma
9.3 Online Pharmacy

10. Region - Global Age Related Macular Degeneration Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa

11. Key Players Analysis
11.1 F. Hoffmann - La Roche Ltd.
11.1.1 Overview
11.1.2 Recent Development
11.1.3 Financial Insight
11.2 Bayer AG
11.2.1 Overview
11.2.2 Recent Development
11.2.3 Financial Insight
11.3 Abbvie
11.3.1 Overview
11.3.2 Recent Development
11.3.3 Financial Insight
11.4 GSK Plc
11.4.1 Overview
11.4.2 Recent Development
11.4.3 Financial Insight
11.5 Novartis AG
11.5.1 Overview
11.5.2 Recent Development
11.5.3 Financial Insight
11.6 Regeneron Pharmaceuticals
11.6.1 Overview
11.6.2 Recent Development
11.6.3 Financial Insight
11.7 Bausch Health Companies Inc.
11.7.1 Overview
11.7.2 Recent Development
11.7.3 Financial Insight
11.8 Alimera Sciences Inc.
11.8.1 Overview
11.8.2 Recent Development
11.8.3 Financial Insight

List of Figures:
Figure 01: Global - Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 02: Global - Forecast for Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 03: Type - Dry Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 04: Type - Forecast for Dry Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 05: Type - Wet Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 06: Type - Forecast for Wet Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 07: Product - Eylea Market (Billion US$), 2018 - 2022
Figure 08: Product - Forecast for Eylea Market (Billion US$), 2023 - 2028
Figure 09: Product - Lucentis Market (Billion US$), 2018 - 2022
Figure 10: Product - Forecast for Lucentis Market (Billion US$), 2023 - 2028
Figure 11: Product - Beovu Market (Million US$), 2018 - 2022
Figure 12: Product - Forecast for Beovu Market (Million US$), 2023 - 2028
Figure 13: Product - Others Market (Billion US$), 2018 - 2022
Figure 14: Product - Forecast for Others Market (Billion US$), 2023 - 2028
Figure 15: Distribution Channel - Hospital Pharmacy Market (Billion US$), 2018 - 2022
Figure 16: Distribution Channel - Forecast for Hospital Pharmacy Market (Billion US$), 2023 - 2028
Figure 17: Distribution Channel - Specialty Pharma Market (Billion US$), 2018 - 2022
Figure 18: Distribution Channel - Forecast for Specialty Pharma Market (Billion US$), 2023 - 2028
Figure 19: Distribution Channel - Online Pharmacy Market (Million US$), 2018 - 2022
Figure 20: Distribution Channel - Forecast for Online Pharmacy Market (Million US$), 2023 - 2028
Figure 21: North America - Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 22: North America - Forecast for Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 23: Europe - Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 24: Europe - Forecast for Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 25: Asia Pacific - Age Related Macular Degeneration Market (Billion US$), 2018 - 2022
Figure 26: Asia Pacific - Forecast for Age Related Macular Degeneration Market (Billion US$), 2023 - 2028
Figure 27: Latin America - Age Related Macular Degeneration Market (Million US$), 2018 - 2022
Figure 28: Latin America - Forecast for Age Related Macular Degeneration Market (Million US$), 2023 - 2028
Figure 29: Middle East & Africa - Age Related Macular Degeneration Market (Million US$), 2018 - 2022
Figure 30: Middle East & Africa - Forecast for Age Related Macular Degeneration Market (Million US$), 2023 - 2028
Figure 31: F. Hoffmann - La Roche Ltd. - Global Revenue (Billion US$), 2018 - 2022
Figure 32: F. Hoffmann - La Roche Ltd. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 33: Bayer AG - Global Revenue (Billion US$), 2018 - 2022
Figure 34: Bayer AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 35: Abbvie - Global Revenue (Billion US$), 2018 - 2022
Figure 36: Abbvie - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 37: GSK Plc - Global Revenue (Billion US$), 2018 - 2022
Figure 38: GSK Plc - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 39: Novartis AG - Global Revenue (Billion US$), 2018 - 2022
Figure 40: Novartis AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 41: Regeneron Pharmaceuticals - Global Revenue (Billion US$), 2018 - 2022
Figure 42: Regeneron Pharmaceuticals - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 43: Bausch Health Companies Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 44: Bausch Health Companies Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 45: Alimera Sciences Inc. - Global Revenue (Million US$), 2018 - 2022
Figure 46: Alimera Sciences Inc. - Forecast for Global Revenue (Million US$), 2023 - 2028

List of Tables:
Table 01: Global - Age Related Macular Degeneration Market Share by Type (Percent), 2018 - 2022
Table 02: Global - Forecast for Age Related Macular Degeneration Market Share by Type (Percent), 2022 - 2028
Table 03: Global - Age Related Macular Degeneration Market Share by Product (Percent), 2018 - 2022
Table 04: Global - Forecast for Age Related Macular Degeneration Market Share by Product (Percent), 2022 - 2028
Table 05: Global - Age Related Macular Degeneration Market Share by Distribution Channel (Percent), 2018 - 2022
Table 06: Global - Forecast for Age Related Macular Degeneration Market Share by Distribution Channel (Percent), 2022 - 2028
Table 07: Global - Age Related Macular Degeneration Market Share by Region (Percent), 2018 - 2022
Table 08: Global - Forecast for Age Related Macular Degeneration Market Share by Region (Percent), 2022 - 2028

Companies Mentioned

  • F- Hoffman - La Roche Ltd.
  • Bayer AG
  • Abbvie
  • GSK Plc.,
  • Novartis AG,
  • Regeneron Pharmaceuticals
  • Bausch Health Companies
  • Alimera Sciences Inc

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...